🔗 Share this article

The initial novel therapies for gonorrhoea in decades are being hailed as a "huge turning point" in the effort against increasingly resistant strains of the bacteria, according to scientists.

A Global Challenge

Cases of gonorrhoea are escalating globally, with data suggesting more than 82 million infections annually. Especially elevated rates are reported in the African continent and nations within the World Health Organization's Western Pacific region, which spans from China and Mongolia to New Zealand. Within England, cases have hit a record high, while infection numbers across Europe in 2023 were three times higher compared to figures for 2014.

“The clearance of new treatments for gonorrhoea is an critical and opportune advancement in the face of rising global incidence, increasing antimicrobial resistance and the highly restricted therapeutic options at this time.”

Health officials are increasingly worried about the surge in antibiotic-resistant strains. The World Health Organization has designated it as a "priority pathogen". Recent surveillance found that the effectiveness of primary antibiotics like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

Two New Therapies Gain Approval

One new antibiotic, marketed under the name Nuzolvence, was cleared by the US FDA in recent days for combating gonorrhoea. This STI can lead to significant complications, including infertility. Researchers hope that targeted use of this new drug will help delay the development of resistance.

Gepotidacin, developed by the pharmaceutical company GSK, was also approved in the same week. This treatment, which is employed against urinary tract infections, was proven in research to be able to combat superbug versions of the gonorrhoea bacteria.

A Novel Partnership

This new treatment was the result of a unique collaborative effort for antibiotic development. The charitable organization Global Antibiotic Research & Development Partnership worked alongside the drug firm its industry partner to bring it to fruition.

“This milestone signifies a significant shift in the management of multidrug-resistant gonorrhoea, which previously has been outpacing antibiotic development.”

Research Study Results and Global Access

According to results published in a prominent scientific publication, zoliflodacin eradicated the vast majority of genital gonorrhoea infections. This puts it on an comparable level with the typical regimen, which involves a dual-drug approach. The research involved nearly 1,000 volunteers from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its development partnership, GARDP has the authority to license and sell the drug in numerous developing nations.

Doctors treating patients have voiced optimism. Having a one-pill regimen like this is hailed as a "critical tool" for gonorrhoea control. This is deemed crucial to reduce the burden of the illness for individuals and to prevent the spread of untreatable gonorrhoea globally.